Patent intelligence · US
US 8415332
Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
Patent details — US 8415332
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 9, 2013
- Expiration
- Apr 4, 2033
- Applicant
- Teva Womans's Health, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/56, A61K31/567, A61K31/57
Quick answer
US 8415332 (Methods of hormonal treatment utilizing ascending-dose extended cycle regimens) is held by Teva Womans's Health, Inc.. Status: granted. Granted Apr 9, 2013. Expires Apr 4, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Teva Womans's Health, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/56, A61K31/567, A61K31/57, A61P, A61P15/18
More from Teva Womans's Health, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 8415332?
US 8415332 (Methods of hormonal treatment utilizing ascending-dose extended cycle regimens) is held by Teva Womans's Health, Inc.. Status: granted. Granted Apr 9, 2013. Expires Apr 4, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8415332?
Teva Womans's Health, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 8415332 expire?
Our index shows an expiration date of Apr 4, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.